<DOC>
	<DOCNO>NCT00425191</DOCNO>
	<brief_summary>To assess antitumour activity ( response rate ) patient locally advanced metastatic non-small cell lung cancer ( NSCLC ) two different combination docetaxel gemcitabine sequential treatment cisplatin /gemcitabine follow docetaxel first line chemotherapy · To evaluate quantitative qualitative toxicity treatment arms.· To determine time progression , duration response , time treatment failure , overall survival group.· To evaluate change baseline Lung Cancer Symptom Scale patient treatment arm .</brief_summary>
	<brief_title>Taxotere Combinations First Line Therapy Locally Advanced Unresectable Metastatic Non-small Cell Lung Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>The following information clinical trial provide information purpose allow patient physician initial discussion trial . This information intend complete information trial , contain consideration may relevant potential participation trial , replace advice personal physician health professional . Main criterion list hereafter : Histologically cytologically confirm diagnosis NSCLC istologic subtypes may include large cell , squamous cell , adenocarcinoma generic cytological diagnosis NSCLC ; Patients must locoregionally advance unresectable non metastatic NSCLC Stage IIIB ( N3 supraclavicular T4 pleural effusion ) Stage IV accord revise International Staging System Patients must least one measurable lesion ; Previous radical surgery ( 30 day study entry ) allow pathologic proof progression neoplastic disease must document whenever possible ; Weight loss &lt; = 5 % within last 3 month ; Laboratory requirement entry : Blood cell count : Absolute neutrophils &gt; 2.0 x 109/LPlatelets &gt; 100 x 109/LHemoglobin &gt; 10 g/dl Renal function : Serum creatinine &lt; 1 upper normal limit ( UNL ) . In case limit value serum creatinine , creatinine clearance &gt; 60 mL/min Hepatic function : Serum bilirubin &lt; 1 x UNLASAT ALAT &lt; 2.5 x UNLAlkaline phosphatase &lt; 5 x UNL ( unless accompany extensive bone metastasis ) ; Exclusion criterion : Prior systemic chemotherapy immunotherapy include neoadjuvant adjuvant treatment ; Prior radiotherapy NSCLC ; Cytohistological diagnosis small cell lung cancer , carcinoid , mixed smallcell / nonsmall cell lung cancer ; Patients measurable disease ; Patients symptomatic brain metastasis leptomeningeal disease . However ; patient symptomatic brain metastases become asymptomatic corticosteriods treatment enter study ; History prior malignancy , except cure non melanoma skin cancer , curatively treat situ carcinoma cervix cancer curatively treat evidence disease least five year ; History hypersensitivity reaction polysorbate 80 ; Pregnant lactate woman ( woman childbearing potential must use adequate contraception ) ; Concurrent treatment experimental drug ; Current peripheral neuropathy NCI grade &gt; = 2 ; Significant neurological psychiatric disorder ; Hepatic function abnormality ; Participation clinical trial experimental agent within 30 day study entry ; Other serious concomitant illness medical condition ; History significant neurologic psychiatric disorder include demential seizure ; Active infection require iv antibiotic ; Active ulcer , unstable diabetes mellitus contraindication corticotherapy ; Any condition , judgement investigator would place subject , undoes risk interferes study . Treatment biphosphonates .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>